These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16507988)

  • 1. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.
    Dezfouli S; Bakke A; Huang J; Wynshaw-Boris A; Hurlin PJ
    Mol Cell Biol; 2006 Mar; 26(6):2080-92. PubMed ID: 16507988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
    Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
    Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Of Myc and Mnt.
    Hooker CW; Hurlin PJ
    J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
    Popov N; Wahlström T; Hurlin PJ; Henriksson M
    Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
    Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
    Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.
    Hurlin PJ; Zhou ZQ; Toyo-oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
    EMBO J; 2003 Sep; 22(18):4584-96. PubMed ID: 12970171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mnt takes control as key regulator of the myc/max/mxd network.
    Wahlström T; Henriksson M
    Adv Cancer Res; 2007; 97():61-80. PubMed ID: 17419941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
    Link JM; Hurlin PJ
    Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
    Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
    J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mnt modulates Myc-driven lymphomagenesis.
    Campbell KJ; Vandenberg CJ; Anstee NS; Hurlin PJ; Cory S
    Cell Death Differ; 2017 Dec; 24(12):2117-2126. PubMed ID: 28800127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Max binding protein as a novel binding protein of Nck1 and characterization of its role in inhibiting human liver cancer SK-HEP-1 cells.
    Zhou Q; Huang T; Wang YF; Zhang KS; Chen D; Peng BG
    Chin Med J (Engl); 2012 Sep; 125(18):3336-9. PubMed ID: 22964333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.
    Link JM; Ota S; Zhou ZQ; Daniel CJ; Sears RC; Hurlin PJ
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19685-90. PubMed ID: 23150551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC needs MNT.
    Link JM; Hurlin PJ
    Cell Cycle; 2013 Feb; 12(3):385-6. PubMed ID: 23324353
    [No Abstract]   [Full Text] [Related]  

  • 14. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.
    Yang H; Li TW; Ko KS; Xia M; Lu SC
    Hepatology; 2009 Mar; 49(3):860-70. PubMed ID: 19086036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
    Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc.
    Mauleon I; Lombard MN; Muñoz-Alonso MJ; Cañelles M; Leon J
    Mol Carcinog; 2004 Feb; 39(2):85-90. PubMed ID: 14750213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mnt: master regulator of the Max network.
    Nilsson JA; Cleveland JL
    Cell Cycle; 2004 May; 3(5):588-90. PubMed ID: 15107624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.
    Nilsson JA; Maclean KH; Keller UB; Pendeville H; Baudino TA; Cleveland JL
    Mol Cell Biol; 2004 Feb; 24(4):1560-9. PubMed ID: 14749372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
    Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
    J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
    Zhang Z; Sun H; Dai H; Walsh RM; Imakura M; Schelter J; Burchard J; Dai X; Chang AN; Diaz RL; Marszalek JR; Bartz SR; Carleton M; Cleary MA; Linsley PS; Grandori C
    Cell Cycle; 2009 Sep; 8(17):2756-68. PubMed ID: 19652553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.